External link, please review our disclaimer.

Guidelines for Establishing and Operating a Data and Safety Monitoring Board - Appendix 1

Initial Protocol Review

Outline of protocol items to be reviewed

Statement of protocol design (e.g., blinding, control group)

Characteristics of study data collection site(s)

Inclusion/exclusion criteria

Randomization/stratification plan

Definition of participants (e.g., screened, enrolled, randomized, training, treated, drop out, lost to follow-up)

Intervention definition

  • Dosage and frequency
  • Manual (specification for behavioral studies)

Reasons to discontinue participation

  • Safety rules
  • Behavioral rules
  • Missed assessments rules

Reasons to change treatment regimen

Outcome measures

  • Primary
  • Secondary

Sample size

  • Calculation
  • Definition of subjects used for calculation (usually those randomized)

Key adherence variables

Key safety variables (e.g., BP, pulse, liver function tests)

Data analysis plan

Interim analysis plan

This page was last updated March 16, 2004.

Search for Funding

Featured Publication

Mentoring, A Guide for Drug Abuse Researchers publication cover

Mentoring: A Guide for Drug Abuse Researchers

Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site